Evidence map›Paper›PMID 41948587›Full record

ArticleFrontiers in medicine2026

Aldehyde

Weiyong Xu, Shunfa Wang, Huaqing Yao, Rongtai Luo, Pu Li, Xinping Lan

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Weiyong XuCenter for Cardiovascular Diseases, Meizhou People's Hospital, Meizhou, China.
Shunfa WangCenter for Cardiovascular Diseases, Meizhou People's Hospital, Meizhou, China.
Huaqing YaoCenter for Cardiovascular Diseases, Meizhou People's Hospital, Meizhou, China.
Rongtai LuoCenter for Cardiovascular Diseases, Meizhou People's Hospital, Meizhou, China.
Pu LiCenter for Cardiovascular Diseases, Meizhou People's Hospital, Meizhou, China.
Xinping LanCenter for Cardiovascular Diseases, Meizhou People's Hospital, Meizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a risk for coronary atherosclerosis. However, some T2DM patients are prone to coronary atherosclerosis, while another group do not suffer from it. Are there any risk factors for T2DM patients to develop coronary atherosclerosis? Aldehyde dehydrogenase 2 (ALDH2) is an important enzyme for the oxidation metabolism of aldehyde substances, and it is related to coronary atherosclerosis. The aim of this study is to analyze the relationship between

Indexed as

ALDH2coronary atherosclerosisrisksusceptibilitytype 2 diabetes mellitus

Identifiers

PMID41948587
PMCPMC13051303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.